Skip to content
Biodatica
Start free

Mezzion Pharma Co. Ltd

Indianapolis, Indiana

Oncologygene editingPhase II
Compare Sign in to watch

What changed

NIH R21 · $0.2M · Mechanism of neutrophil dysfunction by Plasmodium falciparum secreted histidine-rich protein II

Jun 2025Grant renewalJun 13, 2025Source filing (opens the source filing in a new tab)

Momentum

53no change

Momentum 53 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

762 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Grant

    R01 · $442k · non-dilutive

    May 1, 2025

    UNIVERSITY OF PENNSYLVANIA · PI KAPLAN, DAVID E · NCI · award ends Apr 30, 2030 · The role of immunosuppression and environmental exposures on incident and subsequent keratinocyte carcinoma risk after solid organ transplant

    NIH RePORTER · NIH RePORTER 11132052 (opens the source filing in a new tab)

  2. Grant

    R21 · $194k · non-dilutive

    Jul 22, 2024

    WASHINGTON UNIVERSITY · PI GOLDBERG, DANIEL E. · NIAID · award ends May 31, 2027 · Mechanism of neutrophil dysfunction by Plasmodium falciparum secreted histidine-rich protein II

    NIH RePORTER · NIH RePORTER 11142404 (opens the source filing in a new tab)

  3. Grant

    R01 · $491k · non-dilutive

    Mar 1, 2017

    UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAPLAN, DANIEL H · NIAMS · award ends May 31, 2027 · Immune Functions of Cutaneous Nociceptors

    NIH RePORTER · NIH RePORTER 11095711 (opens the source filing in a new tab)

  4. Trial

    PHASE1/PHASE2 registered

    Jul 1, 2014

    Single Ventricle Heart Disease After Fontan Surgery · COMPLETED · sponsor: Mezzion Pharma Co. Ltd · Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents

    ClinicalTrials.gov · NCT02201342 (opens the source filing in a new tab)

  5. Grant

    T32 · $573k · non-dilutive

    Sep 15, 1980

    WASHINGTON UNIVERSITY · PI GOLDBERG, DANIEL E. · NIAID · award ends Apr 30, 2027 · Infectious Disease/Basic Microbial Pathogenic Mechanisms

    NIH RePORTER · NIH RePORTER 11094778 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources